NIH Granted Gene Therapy Patent

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

WASHINGTON--The U.S. Patent and Trademark Office has awarded a broad patent on gene therapy to the National Institutes of Health. Six years after filing the application, NIH and its licensee, Genetic Therapy, Inc. of Gaithersburg, Maryland, can now use the patent for ex vivo human gene therapy.

WASHINGTON--The U.S. Patent and Trademark Office has awarded abroad patent on gene therapy to the National Institutes of Health.Six years after filing the application, NIH and its licensee,Genetic Therapy, Inc. of Gaithersburg, Maryland, can now use thepatent for ex vivo human gene therapy.

In this technique, human cells are manipulated in the laboratoryto express potentially therapeutic genes, which are then introducedinto a patient to treat disease. Coinventors of the techniqueare Michael Blaese, MD, and Stephen A. Rosenberg, MD, PhD, bothNIH scientists, and W. French Anderson, MD, a former NIH researchernow at the University of Southern California Norris Cancer Center.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content